Navigating Camp Lejeune Compensation: Beyond the Elective Option

Dec 13, 2023 | 0 comments

As the Camp Lejeune case progresses, the focus shifts to the qualifying conditions for compensation, prompting questions about the criteria. While federal guidelines provide a list of presumptive conditions for compensation, there is a growing awareness that non-presumed conditions, already attributed by the VA to Camp Lejeune water exposure, might yield significant awards.

A pending report from the Agency for Toxic Substances and Disease Registry (ATSDR) is anticipated to be released in the coming weeks, potentially broadening the spectrum of injuries linked to the contaminated water at Camp Lejeune.

The Elective Option Debate

In recent months, an elective compensation option has been presented, sparking debate among plaintiff lawyers. Many have opted to dismiss this initial offer due to relatively low awards. Statistics reveal that out of sixteen offers, only four have been accepted, with a total payout of less than $1 million. This indicates a reluctance among claimants to opt for the elective route, attributing it to its limited compensation and advocating for patience in favor of individual settlement discussions or trial.

The elective option covers two tiers of conditions, including cancers and disorders, but the low acceptance rate suggests it may not be the best choice for a majority of claimants.

A Case in Point

Beasley Allen, a prominent firm, expressed that less than 2% of their clients both qualified and opted for the elective option. They emphasized that this option might only be suitable for individuals in dire financial straits, with a short life expectancy, or weak cases. Their assertion is that waiting may yield higher compensation for all claimants.

As of now, only three of their clients have been paid via the elective option, totaling $850,000.

The Slow Progress of the Elective Option

The elective option settlement process has been notably slow, with only sixteen cases accepted by the Department of Justice (DOJ) as of November 27. Out of these, only four offers were accepted, two were rejected, six expired, and eight are still pending. This sluggish pace raises questions about the effectiveness of the entire program.

Beyond Tiers: Exploring Other Compensation Avenues

For individuals without conditions listed in the elective option tiers, hope is not lost. The ATSDR report, although yet to be released, suggests that additional diseases and conditions could be considered for compensation under the Camp Lejeune Justice Act of 2022 and PACT.

While specific details are awaited, preliminary information hints at a broader list of cancers and disorders associated with Camp Lejeune water exposure. Male breast cancer, miscarriage, and female infertility are among the potential considerations. Interestingly, these conditions, while covered under the Camp Lejeune Justice Act, are ineligible under the elective option.

The disparity between the elective option list and the VA's coverage further complicates matters, leaving room for uncertainty. Plaintiff attorneys are grappling with this issue, emphasizing that the elective option should not be viewed as the standard for Camp Lejeune cases.

Looking Ahead

As we await more definitive news, it becomes clear that the elective option's list of conditions is not exhaustive. Additional conditions may be added, and other compensation avenues, including litigation, remain viable. The advice to legal practitioners is clear – patience may lead to better outcomes for clients. Reconsideration of cases previously rejected due to certain conditions, such as breast or lung cancer, may be warranted, as these cases could hold value and potentially offer higher compensation than those covered by the elective option.

Best Case Leads Celebrates Sixth Consecutive Year on Inc. 5000 List of Fastest-Growing Private Companies in America

Aug 19, 2025 | Press Releases Houston, TX, August 18, 2025 — Best Case Leads, a pioneering leader in legal lead generation, proudly announces its sixth consecutive recognition on the prestigious Inc. 5000 fastest-growing private companies in...

Baby Formula Litigation, NEC Claims, and the Evolving Landscape of Mass Torts

By Fadi Agour, J.D. Families of premature infants who developed necrotizing enterocolitis (NEC) after being fed cow–milk–based formula products like Similac and Enfamil continue to pursue justice in both state and federal courts. Recent...

Mass Tort Landscape 2025: Key Cases, Trends & Strategic Opportunities

The mass tort landscape is evolving rapidly, with new cases gaining momentum and established litigations reaching critical phases. For law firms and legal marketers, timing is everything—success hinges on anticipating trends, securing high-value claimants early, and...

Zyprexa & Risperdal 2: The Breast Cancer Link That Could Ignite the Next Mass Tort

The pharmaceutical litigation landscape has seen its share of blockbuster cases—from opioid multidistrict litigations to the ongoing Paraquat Parkinson’s claims. But a new California lawsuit (Brown v. Johnson & Johnson et al.) could revive two legacy antipsychotics...

Mass Torts in 2025: A Legal Landscape in Flux

As 2025 unfolds, the world of mass tort litigation shows no signs of slowing down. From pharmaceutical giants to tech behemoths, corporations across industries are facing an unprecedented wave of lawsuits that could reshape their futures. With judges issuing critical...

The PFAS Contamination Crisis: A Deep Dive into the Mass Tort Litigation and Its Implications

Per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a focal point of environmental and public health concerns in the United States. These synthetic chemicals, used for their water, heat, and grease-resistant properties,...

The Ultra-Processed Foods Lawsuit: A Must-Know Update for Mass Tort Lawyers

Ultra-processed foods (UPFs) have become a cornerstone of modern diets, but their convenience comes at a cost. As consumption of these foods has skyrocketed, so too have the alarming health complications linked to them, including obesity, diabetes, heart disease, and...

Understanding the BioZorb Litigation: A Growing Legal Battle for Plaintiff Attorneys

What is BioZorb? The BioZorb litigation is shaping up to be one of the most significant legal challenges of 2025, presenting a unique opportunity for plaintiff attorneys nationwide. This case revolves around a medical device designed to aid breast cancer patients but...

The Role of Technology in Optimizing Workers’ Compensation Lead Generation

The process of generating and managing workers' compensation leads has undergone a significant transformation with the advent of technology. Modern tools and software solutions are now indispensable in streamlining operations, improving lead quality, and enhancing...

How to Build a Referral Network for Mass Tort Cases

Mass tort cases often involve a large number of claimants seeking justice for harm caused by a common defendant, such as pharmaceutical companies or manufacturers. For attorneys specializing in these cases, building a robust referral network can significantly boost...

Ready to Start Receiving Qualified Leads?

Get exclusive, real-time legal leads delivered to your firm.

Get Started